Compare your deck to Theranos

Compare Your Deck

Cautionary Tale

Theranos Pitch Deck (2006)

Cautionary Tales

Stage: Series C

Raised: $28.5M+

Year: 2006

Slides: 24

Outcome: FAILED - Fraud, dissolved

Pitch Deck

1 / 24

Click to expand

Deck Analysis

This deck is Theranos's Series C investor presentation from 2006. It presents a bold vision: a low-volume blood-testing cartridge and reader plus an informatics backend to enable real-time drug monitoring and post-prescription patient management. The slides mix product imagery, performance claims, clinical use-cases and large market estimates to make a fast, venture-friendly story — notable both for how convincingly it packaged a complex technology for investors and, retrospectively, for how many high‑impact claims went insufficiently substantiated before massive capital was raised and the company ultimately failed amid fraud allegations.

The Opening: Clear branding and investor framing

Slide 1 is the simple cover page with the Theranos logo, the phrase 'A Presentation For Investors' and a date (June 1, 2006). It’s minimal and professional, immediately signaling the audience and purpose. For investors, this sets expectations: a focused pitch, not a product brochure. The design is clean and unobtrusive, which helps direct attention to the name and the ask that follows.

Key Takeaway: Start with a clean, audience-specific cover that signals purpose and date — small details build credibility.

Company overview and go-to-market focus

Slide 2 lays out the company's immediate goal, initial market (Phase IV clinical trials), product platform (cartridges, readers, informatics) and basic company facts (founded 2003, Menlo Park, 50 employees). This is effective because it quickly answers the who/what/where/why that investors want and ties the technology to a specific commercial entry point (post-marketing clinical trials) rather than an abstract 'healthcare' promise. Framing the initial market narrowly helps investors assess near-term traction potential and the revenue model.

Key Takeaway: Define a realistic initial beachhead market and explain the product components that map directly to that market.

Team slide: show depth but avoid vague credentials

Slide 4 (Management) lists leadership and board members with short bios and past affiliations. It attempts to reassure investors by mixing industry veterans and technical leads. A strong team slide pairs relevant experience with clear roles; investors look for operational and scientific credibility. Theranos’s slide shows that principle: it highlights executives with prior exits and big-company experience to suggest the capacity to scale.

Key Takeaway: List leaders and board members with concise, relevant credentials and quantifiable achievements to give investors confidence — but also ensure governance and transparent validation.

Product visuals and the ‘what is our system’ story

Slide 5 shows photos of cartridges, readers and a compact instrument, plus a simple graph. Visuals make the product tangible: investors can see scale, form factor and that some prototype exists — important for hardware and diagnostics companies. The deck uses imagery to bridge the technical world and the investor's need to believe something physical is being built. Showing multiple views (cartridge, internal components, and a result curve) is a good way to communicate complexity without overwhelming.

Key Takeaway: Use clear, honest product photos and representative outputs to make the technology tangible — but pair them with objective validation data.

Product features and technical claims

Slide 9 (Product Features) lists key technical specs: sample size (5–10 µL), time to result (<30 minutes), operating principle (chemiluminescent/immunoassay), precision (5–7% CV), immediate upload to secured server, and an attractive development timeline for new assays. This succinct, bullet‑point approach is effective because it addresses common diligence questions—sample volume, throughput, accuracy and data handling—without bogging down the deck.

Key Takeaway: State core technical specifications clearly and concisely, and be prepared to substantiate each claim with protocol-level data and third-party comparisons.

Market sizing and revenue assumptions

Slide 14 provides TAM details for Phase IV clinical trials: a $39B/year market, 600–800 ongoing trials, average Theranos revenue per trial of $50M, and an information fee model per patient. This is classic VC-facing math: combine a credible market segment with a clear monetization model to arrive at large revenue potential. Presenting trial counts and average revenue per trial helps investors do back-of-envelope checks quickly.

Key Takeaway: Show TAM with clear unit economics and conservative adoption assumptions; make it easy for investors to sanity-check your revenue math.

The offering and investor list: clarity and credibility

Slide 20 (Offering) states the fundraising objective ($30M), and splits expected allocation between existing and new investors. Slide 21 (Existing Investors) lists lead investor profiles across Series A and B, naming recognizable funds and individuals. This combination does two important things: it gives a clear ask and shows momentum/backing, which reduces perceived risk for new investors.

Key Takeaway: Be explicit about the round size, allocation and use of funds, and highlight reputable existing investors — but make sure commitments are accurate and supported.

Conclusion: Key Lessons

Theranos’s Series C deck is a strong example of investor-focused storytelling: clear branding, a defined beachhead market, tangible product visuals, succinct technical claims and ambitious market math. These are the right elements for a hardware/diagnostics raise and helped Theranos raise large sums quickly. However, the deck also illustrates critical pitfalls: grand claims without transparent, reproducible validation, optimistic TAM/conversion assumptions without conservative scenarios, and over-reliance on reputation rather than demonstrable, auditable performance.

For founders: craft a crisp narrative that ties product, market and monetization together; use visuals and a team slide to build trust; but pair every performance and market claim with verifiable evidence (protocols, blinded comparisons, regulatory milestones, and third-party data). Be conservative in your financial assumptions, transparent about use of funds, and ensure governance and data integrity are front and center — those are the factors that protect investors and founders alike as a company scales.

Compare Your Deck To Theranos

Full Deck Analysis

11 sections

Overview Executive Summary Problem Statement Solution Market Opportunity Business Model Traction & Metrics Competitive Positioning Team Go-to-Market Strategy The Ask

Overview

Company: Theranos
Round: Series C ($28.5M+)
Year: June 1, 2006
Outcome: FAILED - Fraud, dissolved 2018
Status: Cautionary case study of fraudulent pitch deck

Executive Summary

The Theranos Series C pitch deck is a masterclass in fraudulent pitching that successfully raised $28.5M+ despite lacking fundamental validation. Across 23 slides, the company makes extraordinary claims about blood testing technology with virtually no supporting evidence, constantly pivots its business model (6+ different markets), and reveals fundamental technical problems while attempting to hide them. The deck demonstrates how charisma, vague language, investor backing, and FOMO can overcome the absence of peer-reviewed publications, FDA approvals, customer validation, or clinical data. This case study is essential reading for understanding how sophisticated fraud can be perpetrated through professional pitch decks.

Problem Statement

How the Deck Articulates the Problem

Slide 17: “Pains In The Existing Marketplace” identifies five market problems:

Adverse Drug Reactions (ADRs) reduce sales and keep drugs off market
Pharmacogenomic tests don’t eliminate ADRs and screen out patients who could benefit
No mechanism to measure environmental factors on drug efficacy
No continuous monitoring to determine correct dosage
Current testing procedures too expensive or impossible for some drugs

Critical Issue with Problem Statement

The identified problems do not align with the proposed solution:

Problems focus on drug safety and efficacy optimization
Solution is drug level monitoring (therapeutic drug monitoring)
These are complementary, not competitive solutions
Suggests company is working backwards: starting with a solution and trying to find problems it solves

Problems Never Clearly Defined

Slide 2: Mission is vague (“become the standard for improving…every therapy”)
Slides 3-6: No clear explanation of what Theranos actually does
Slide 5: First hardware shown without explanation of purpose
Slide 6: System architecture shown without explaining what it measures
Result: By Slide 17, the actual problem remains unclear

Solution

What Theranos Claims to Offer

Slide 18: “Theranos Solution” lists 10 claimed benefits:

Monitoring can take place anywhere and be done by anyone
Monitoring can be as frequent as needed with little cost increase
Results compare to/beat blood lab results
Results available in minutes
Warning to doctor within minutes of test
Effectiveness of dose monitored in real time
Drug-drug combinations monitored to improve label
Drugs prescribed with monitoring devices to prevent ADRs
Instant analysis improves speed and effectiveness of trials
Consumer portal increases patient compliance

The Technology (Slides 5-6, 22-23)

Hardware Components:

Cartridge: Disposable microfluidic device (orange/red layered design)
Reader: Dark blue/black optical reader device
Informatics System: Large cabinet + desktop computers

Operating Principle:

Chemiluminescent/immunoassay (Slide 8)
Microfluidic technology (implied but never explicitly stated)
Server-based calibration (Slide 23 - major red flag)

Claimed Specifications (Slide 8):

Sample size: 5-10µL blood
Turnaround time: < 30 minutes for multiplex assays
Precision: 5-7% Coefficient of Variation
Dynamic range: Picogram/mL to microgram/mL (6+ orders of magnitude)
Accuracy: “Comparable to gold standards” (unspecified)
On-board calibration/control with each measurement

Critical Problem Revealed (Slide 23)

Server-based calibration to “preempt use of environmentally deteriorated cartridges”

Cartridges deteriorate in the field
Company uses remote server to detect and compensate for deterioration
This is non-standard, unvalidated, and raises data integrity concerns
Suggests fundamental manufacturing/stability problem

Market Opportunity

Market Sizing Claims (Slides 14-15)

Slide 14: Phase IV Clinical Trials Market

Total market: $39 Billion per year
Number of ongoing trials: 600-800 per year
Average Theranos revenue per trial: $50M
Information fee: $7,500 per patient per 4 months ($22,500/year)
Patients per trial: 2,000-10,000

Calculation Logic:

Low end: 2,000 patients × $7,500 × 3 cycles/year = $45M per trial
High end: 10,000 patients × $7,500 × 3 cycles/year = $225M per trial
Average: ~$50M per trial

Slide 15: Pharmaceutical Preclinical Market

Total market: $10 Billion per year
Revenue per research group: $5M annually
Groups per pharmaceutical company: 133
Companies of this size: 15
Note: Excludes academic institutions (largest segment)

Critical Issues with Market Sizing

No sources cited — all numbers are unsubstantiated
Assumes 100% market capture — unrealistic for a startup
No competitive analysis — how would Theranos capture this market?
Revenue model unjustified — why would customers pay $7,500 per patient per 4 months?
Multiple markets — company pivots between Phase IV trials, preclinical research, chemotherapy monitoring, telemedicine
No evidence of customer willingness to pay — no customer validation

TAM/SAM/SOM Analysis

Metric	Claimed	Reality
TAM (Total Addressable Market)	$39B (Phase IV) + $10B (preclinical) = $49B	Unsubstantiated; assumes 100% addressability
SAM (Serviceable Addressable Market)	Not defined	Unknown; company has no clear focus
SOM (Serviceable Obtainable Market)	Not defined	6 deals with 5 companies = minimal traction
Market Growth Rate	Not addressed	Unknown
Competitive Intensity	Not addressed	High (CROs, diagnostic companies, pharma)

Business Model

Revenue Model (Slide 16)

“Information Fee” Structure:

Bundled service including:
- Hardware (Readers)
- Consumables (Cartridges)
- Software (ABCS informatics)
- Service (Patient diary, data integration)

Pricing:

$7,500 per patient per 4 months (Slide 14)
Implied annual revenue per patient: $22,500

Gross Margins:

Claimed: 70% (Slide 16)
Red flag: Unrealistic for a startup with 50 employees
Typical medical device margins: 40-60%
Diagnostic companies at scale: 50-70%

Unit Economics

Metric	Claimed	Assessment
Price per patient per 4 months	$7,500	Unjustified; no competitive comparison
Cost of goods sold	~$2,250 (30% of revenue)	Unrealistic; no breakdown provided
Gross margin	70%	Unrealistic for startup scale
Customer acquisition cost	Not addressed	Unknown
Lifetime value	Not addressed	Unknown
Payback period	Not addressed	Unknown

Revenue Projections (Slide 3)

Current Status (2006):

6 Deals with 5 companies
No revenue figures disclosed
No indication of deal size or stage

Projections (1.5 years out):

$120M - $1.5B in revenue
Range is 12.5x spread — suggests uncertainty
No breakdown by customer or market segment
No indication of how these projections were derived

Traction & Metrics

Customer Traction (Slide 3)

Current Deals:

6 Deals with 5 companies (unspecified)
1 Government agency (unspecified)
15 additional deals in pipeline (unspecified)

Critical Issues:

No customer names provided
No indication of deal size
No indication of revenue generated
No indication of customer satisfaction
No indication of product usage
For a Series C company, this is minimal traction

Proof Points

Slides 10-12: Chemotherapy Monitoring Case Study

Single patient, three treatment courses
Shows dose adjustment based on drug levels
Problems:
- Only one patient (not statistically significant)
- No clinical outcome data
- No comparison to standard TDM
- No indication of accuracy
- Anecdotal evidence, not validation

Slide 22: Technology Comparison Data

Four graphs comparing Theranos vs. conventional assay
Shows sensitivity, accuracy, calibration, linearity
Problems:
- Poorly labeled graphs
- No sample size information
- No statistical analysis
- No error bars or confidence intervals
- Appears to be preliminary research data, not validated commercial product

Growth Metrics

Metric	Value	Assessment
Customers	5-6 companies	Minimal for Series C
Revenue	Not disclosed	Unknown
Year-over-year growth	Not disclosed	Unknown
Customer retention	Not disclosed	Unknown
Net revenue retention	Not disclosed	Unknown
Burn rate	Not disclosed	Unknown
Runway	Not disclosed	Unknown

Competitive Positioning

Claimed Competitive Advantages (Slide 19)

First mover advantage — FALSE; TDM already exists
Combination of technologies makes reproducing difficult — VAGUE; no specifics
Innovation pipeline: Next generation systems — UNDEFINED; no details
Strong customer base — FALSE; only 6 deals
Speed to market and focus on quality — FALSE; 3 years with no commercial product
Patents — MENTIONED but not detailed
Management and culture — VAGUE; no specifics

Competitive Landscape (Not Addressed)

Existing competitors in therapeutic drug monitoring:

Hospital laboratories (HPLC, LC-MS)
Quest Diagnostics
LabCorp
Roche Diagnostics
Abbott Diagnostics
Siemens Healthcare Diagnostics
Specialized TDM companies

Theranos’s competitive advantages vs. these players:

Not explained
Not demonstrated
Not validated

Differentiation Claims

Claim	Evidence	Assessment
Results in minutes	None	Unsubstantiated
Smaller sample volume	Slide 8 (5-10µL)	Plausible but unvalidated
Better sensitivity	Slide 22 (preliminary data)	Preliminary, not validated
Lower cost	Slide 16 (20-30% savings)	Unjustified
Anywhere, anytime	Slide 18	Unsubstantiated

Team

Executive Team (Slide 4)

Elizabeth Holmes - President and CEO

Background: Stanford Chemical and Electrical Engineering
Red flag: No healthcare/diagnostics background
Also: Genencor, Genome Institute Singapore (roles undefined)
Assessment: Entrepreneur/engineer, not scientist or clinician

Howard Bailey - CFO

Background: Former CFO at QED and Photon Dynamics (public companies)
Also: CFO at Occam, C-Cube; Controller at Intel
Assessment: Finance expert, but background is in semiconductors/optics, not healthcare

Diane Parks - CCO

Background: Former SVP Biotherapeutics and Managed Care at Genentech
Also: VP Marketing at Aventis
Assessment: Healthcare marketing/business development, not diagnostics expert

John Howard - Senior VP Products

Background: Former President, Panasonic Semiconductor; President, IBM Microelectronics Division
Red flag: Semiconductor/microelectronics background, not diagnostics
Assessment: Hardware/tech executive, not diagnostics expert

Dr. Ian Gibbons - Senior Director Assay Development

Background: Former Senior Director at Syva, ACLARA, Biotrack, AmCell, First Medical
Assessment: Only real scientist with actual assay development experience
Red flag: Not Chief Scientific Officer; not in leadership position

Tim Kemp - Senior Director Informatics Systems

Background: Former lead systems engineer, IBM Embedded Systems
Assessment: IT/systems expert, not diagnostics expert

Board of Directors (Slide 4)

Donald L. Lucas - Chairman

46-year veteran of venture capital business
Assessment: VC expert, not healthcare expert

Elizabeth Holmes - CEO

Red flag: CEO on own board (governance concern)

Peter Thomas - Board Member

Founder and Managing Director, ATA Ventures
General Partner, Institutional Venture Partners
Assessment: VC expert, not healthcare expert

Channing Robertson - Board Member

Stanford Senior Associate Dean of Engineering
Assessment: Academic credibility, but engineering dean, not diagnostics expert

Team Assessment

Dimension	Assessment
Healthcare expertise	WEAK - only Dr. Gibbons has relevant background
Diagnostics expertise	WEAK - no one from major diagnostic companies
FDA regulatory expertise	ABSENT - no regulatory expert
Clinical laboratory expertise	ABSENT - no lab director or pathologist
Manufacturing expertise	ABSENT - no manufacturing expert
Alignment with business	POOR - team is tech/semiconductor focused, not healthcare
Leadership depth	WEAK - 50 employees total, limited functional expertise

Go-to-Market Strategy

Market Entry Strategy (Not Clearly Defined)

Slide 14: Phase IV Clinical Trials

Target: Pharmaceutical companies
Approach: Not specified
Sales strategy: Not specified
Customer acquisition cost: Not addressed

Slide 15: Preclinical Research

Target: Pharmaceutical research groups
Approach: Not specified
Sales strategy: Not specified
Customer acquisition cost: Not addressed

Slide 7: ABCS Telemedicine System

Target: HMOs, pharmacies, patients
Approach: Not specified
Sales strategy: Not specified
Customer acquisition cost: Not addressed

Distribution Channels

Mentioned but not detailed:

Direct sales to pharmaceutical companies
Direct sales to research groups
Telemedicine platform (unclear how this works)
“Partner” (undefined on Slide 7)

Sales Force Plan (Slide 20)

Objective: “Add to Theranos business development and sales force”

No details provided:
- How many salespeople will be hired?
- What’s the sales target?
- What’s the sales cycle?
- What’s the customer acquisition cost?
- What’s the sales compensation structure?

Marketing Strategy

Not addressed in the deck

No brand positioning
No marketing budget
No customer acquisition strategy
No messaging framework
No competitive positioning

The Ask

Capital Raise (Slide 20)

Total Offering: $30M

Existing Investors: $15-20M
New Investors: $10-15M

Structure: CFP (Convertible Preferred)

Terms not explained
Conversion terms not specified
Liquidation preference not specified
Dividend rate not specified

Use of Proceeds (Slide 20)

Stated Objective:
“Pre-IPO transaction to facilitate rapid scaling of Theranos production and manufacturing infrastructure and add to Theranos business development and sales force”

Critical Issues:

No detailed breakdown of capital allocation
No timeline for deployment
No milestones tied to capital
No specific targets for manufacturing capacity
No specific targets for sales force size
Investors are being asked to invest $30M without clear use of proceeds

Implied Use of Proceeds (Inferred)

Category	Estimated %	Assessment
Manufacturing infrastructure	Unknown	No manufacturing plan provided
Sales force	Unknown	No sales plan provided
R&D	Unknown	Not mentioned
Operations	Unknown	Not mentioned
Working capital	Unknown	Not mentioned

Valuation

Not provided in the deck

Pre-money valuation: Not stated
Post-money valuation: Not stated
Price per share: Not stated
Dilution to existing shareholders: Not stated
Critical information missing for Series C investors

Path to Exit

Slide 20: “Pre-IPO transaction”

Suggests IPO is imminent
But company has:
- No FDA approvals
- No commercial product
- Minimal customer traction
- No revenue disclosed
- IPO is unrealistic